GYRE_OUT_1 [2025-03-19 14:44:36 -0400] 2163 Bytes | 580 tokens | Cum: 580 tkns (7.25% of 8k)
==========================================================================

We are in the 'Lightning Round' baby! It's 02:44:35 PM on Wednesday March 19, 2025 ET (UTC-0400), and I'm firing up the spotlight on Gyre Therapeutics (GYRE), moving from 8.57 to 9.88. Is this a can’t-miss rocket or a one-hit wonder? Let’s dissect the numbers!

Here's the first list of news for Gyre Therapeutics:

C1 - Mar-17-25 04:15PM - Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
C2 - Jan-06-25 07:00AM - Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors
C3 - Nov-13-24 06:00AM - Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
C4 - Oct-22-24 04:05PM - Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis
C5 - Oct-01-24 04:05PM - Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference
C6 - Sep-04-24 04:05PM - Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
C7 - Aug-13-24 06:00AM - Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
C8 - Aug-09-24 07:00AM - Gyre Therapeutics to Present at Sidoti Virtual Investor Conference

ONLY 3 RULES for AI:
==============
1) This is a document retrieval system. You are the analyst-investigator.
2) You can request items from any list to get more details about Gyre Therapeutics (GYRE)
3) AFTER requesting and reading News and SEC filings you'll get tokens to write a summary, set a score and high price target, and finally take an exit quiz.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.

Thank you for your analysis of Gyre Therapeutics.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!

Please request a document, read, summarize and score. Say something like "C1".

GYRE_OUT_3 [2025-03-19 14:44:41 -0400] 968 Bytes | 295 tokens | Cum: 877 tkns (10.96% of 8k)
==========================================================================

Showing C1 (chunk 1 of 11): C1:
**Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update**
Date: Mar-17-25 04:15PM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/17/3044101/0/en/Gyre-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Provides-Business-Update.html

March 17, 2025 16:15 ET| Source:Gyre Therapeutics Inc.Gyre Therapeutics Inc.

Data from pivotal Phase 3 trial in CHB-associated liver fibrosis expected in Q2 2025

Commercial launch in the PRC of generic nintedanib for the treatment of IPF and avatrombopag maleate tablets for the treatment of CLD-associated thrombocytopenia expected in 2025

Initiation of U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis expected in 2025

Full year 2025totalrevenue guidance of $118 to $128 million

SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Gyre T

-- More? (MOR) or Next section? (NEX)

GYRE_OUT_5 [2025-03-19 14:44:43 -0400] 983 Bytes | 309 tokens | Cum: 1188 tkns (14.85% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-19T16:16:05Z - Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Down on Disappointing Earnings...
A2 - 2025-03-18T20:52:59Z - Gyre Therapeutics (NASDAQ:GYRE) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS...
A3 - 2025-03-18T20:24:51Z - Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells $24,620.00 in Stock...
A4 - 2025-03-18T17:05:47Z - 12 Health Care Stocks Moving In Tuesday's Intraday Session - Gyre Therapeutics (NASDAQ:GYRE), Avenue...
A5 - 2025-03-18T17:30:27Z - S&P 500 Down 1%; Sarepta Therapeutics Shares Plunge - Aditxt (NASDAQ:ADTX), FinVolution Gr (NYSE:FIN...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

GYRE_OUT_7 [2025-03-19 14:44:45 -0400] 967 Bytes | 268 tokens | Cum: 1458 tkns (18.22% of 8k)
==========================================================================

Showing A1 (chunk 1 of 6): A1:
**Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Down on Disappointing Earnings**Date: 2025-03-19Source: {'uri': 'marketbeat.com', 'dataType': 'news', 'title': 'Market Beat'}URL: https://www.marketbeat.com/instant-alerts/gyre-therapeutics-nasdaqgyre-shares-gap-down-on-disappointing-earnings-2025-03-18/Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report)'s share price gapped down before the market opened on Tuesday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $12.28, but opened at $11.50. Gyre Therapeutics shares last traded at $10.07, with a volume of 177,811 shares changing hands.

The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.03). The company had revenue of $27.87 million for the quarter, compared to analyst estimates of $23.50 million. Gyre Therapeutics had a n

-- More? (MOR) or Next section? (NEX)

GYRE_OUT_9 [2025-03-19 14:44:46 -0400] 967 Bytes | 246 tokens | Cum: 1706 tkns (21.32% of 8k)
==========================================================================

Showing A1 (chunk 2 of 6): egative return on equity of 118.43% and a negative net margin of 84.57%.

Analysts Set New Price Targets

Separately, Noble Financial initiated coverage on Gyre Therapeutics in a research report on Tuesday, March 11th. They set an "outperform" rating on the stock.

In related news, President Songjiang Ma sold 2,000 shares of the stock in a transaction dated Thursday, December 26th. The shares were sold at an average price of $12.70, for a total transaction of $25,400.00. Following the sale, the president now owns 2,928,467 shares in the company, valued at $37,191,530.90. This represents a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last three months, insiders sold 36,054 shares of company stock valued at $409,057. Company insiders own 19.52% of

-- More? (MOR) or Next section? (NEX)

GYRE_OUT_11 [2025-03-19 14:44:48 -0400] 1018 Bytes | 299 tokens | Cum: 2007 tkns (25.09% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-06-18T20:05:00Z - Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology
B2 - 2024-05-28T20:05:00Z - Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes
B3 - 2024-05-09T20:10:00Z - Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
B4 - 2024-04-11T17:33:07Z - Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
B5 - 2024-04-11T14:01:51Z - Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
B6 - 2024-03-26T10:00:00Z - Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

GYRE_OUT_13 [2025-03-19 14:44:51 -0400] 467 Bytes | 125 tokens | Cum: 2134 tkns (26.67% of 8k)
==========================================================================

Showing B3 (chunk 1 of 1): B3:
**Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/05/09/2879221/0/en/Gyre-Therapeutics-Reports-First-Quarter-2024-Financial-Results-and-Provides-Business-Update.htmlGyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

-- More? (MOR) or Next section? (NEX)

GYRE_OUT_15 [2025-03-19 14:44:52 -0400] 823 Bytes | 210 tokens | Cum: 2390 tkns (29.88% of 8k)
==========================================================================

This is our list of SEC filings.
Read it just by asking.
Don't miss breaking filings!

S1 - 2025-03-17 10-K Item 7. MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER.

You should read the following discussion and analysis of our financial condition and results of operations together with our audited financial statements and related notes included el...

S2 - 2025-03-17 8-K Item 2.02. Results of Oper and Fin Cond.

On March 17, 2025, Gyre Therapeutics, Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2024 and other matters described. A copy of the press release is furni...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing - but what fun is that?
Response limited to 3 chars.

GYRE_OUT_17 [2025-03-19 14:44:54 -0400] 967 Bytes | 192 tokens | Cum: 2584 tkns (32.30% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 7. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

You should read the following discussion and analysis of our financial condition and results of operations together with our audited financial statements and related notes included elsewhere in this Annual Report on Form 10-K. This discussion and other parts of this Annual Report on Form 10-K contain forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section of this report entitled Risk Factors. You should carefully read the Cautionary Note About Forward-Looking Statements and Risk Factors s

-- More? (MOR) or Next section? (NEX)

GYRE_OUT_19 [2025-03-19 14:44:55 -0400] 967 Bytes | 192 tokens | Cum: 2778 tkns (34.73% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): ections of this Annual Report on Form 10-K to gain an understanding of the important factors that could cause actual results to differ materially from the results described below.

Overview

We are a commercial-stage biotechnology company with a proven track record of financial success developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. Fibrotic diseases represent a large patient population with significant unmet medical needs and involves a complex, multi-stage process with multiple pathways. While there are numerous potential targets for anti-fibrotic therapy, both established and emerging, addressing a single molecular pathway may not be sufficient to prevent, halt, or reverse fibrosis.

Our strategy is to build on our success in the development and commercialization of ETUARY (pi

-- More? (MOR) or Next section? (NEX)

GYRE_OUT_21 [2025-03-19 14:45:07 -0400] 6380 Bytes | 1785 tokens | Cum: 4566 tkns (57.07% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+---------------------+----------------------+------------------------+------------------------+------------------------+
| Prev Close: 8.57 | RSI (14): 41.41 | Perf Quarter: 0.88% | Insider Trans: -0.16% | Sales Q/Q: - | ROE: - |
+---------------------+---------------------+----------------------+------------------------+------------------------+------------------------+
| Target Price: 20.00 | ATR (14): 1.15 | Index: RUT | Option/Short: No / Yes | Sales past 5Y: 309.98% | ROI: 18.82% |
+---------------------+---------------------+----------------------+------------------------+------------------------+------------------------+
| Price: 9.73 | SMA20: -12.76% | Market Cap: 834.64M | Short Float: 8.33% | Income: 12.09M | Sales Surprise: 18.60% |
+---------------------+---------------------+----------------------+------------------------+------------------------+------------------------+
| Change: 13.48% | SMA50: -13.38% | Shs Outstand: 86.31M | Short Ratio: 13.29 | Employees: 5 | EPS Surprise: -100.00% |
+---------------------+---------------------+----------------------+------------------------+------------------------+------------------------+
| Volume: 268,476 | SMA200: -20.43% | Shs Float: 16.16M | Short Interest: 1.35M | Debt/Eq: 0.03 | P/E: 81.59 |
+---------------------+---------------------+----------------------+------------------------+------------------------+------------------------+
| Avg Volume: 101.30K | Perf Week: -16.66% | Inst Own: 2.08% | Beta: 1.93 | Sales Y/Y TTM: - | Earnings: Mar 17 AMC |
+---------------------+---------------------+----------------------+------------------------+------------------------+------------------------+
| Rel Volume: 3.41 | Perf Month: -23.42% | Insider Own: 81.17% | Sales: 105.76M | Profit Margin: 11.43% | |
+---------------------+---------------------+----------------------+------------------------+------------------------+------------------------+

The next section covers any insider trading.
If this section is blank, it's because there've been no recent filings.

Inside Trans: GYRE THERAPEUTICS, INC. (GYRE) by Ma Songjiang (President) on 2025-03-13
- Common Stock: 2000 shares at $11.8 (I) Footnote: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.
- Common Stock: 2000 shares at $12.31 (I) Footnote: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

Inside Trans: GYRE THERAPEUTICS, INC. (GYRE) by Ma Songjiang (President) on 2025-03-11
- Common Stock: 2000 shares at $11.4 (I) Footnote: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.
- Common Stock: 2000 shares at $11.74 (I) Footnote: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

Inside Trans: GYRE THERAPEUTICS, INC. (GYRE) by Ma Songjiang (President) on 2025-03-07
- Common Stock: 53 shares at $13.03 (I) Footnote: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.
- Common Stock: 41 shares at $12.14 (I) Footnote: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.
- Common Stock: 1906 shares at $10.13 (I) Footnote: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.
- Common Stock: 2000 shares at $10.14 (I) Footnote: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

Inside Trans: GYRE THERAPEUTICS, INC. (GYRE) by Ye Weiguo (Chief Operating Officer) on 2025-03-07
- Stock Option (Right to Buy): 300000 shares at $0 (D)

Inside Trans: GYRE THERAPEUTICS, INC. (GYRE) by Ma Songjiang (President) on 2025-03-05
- Common Stock: 2000 shares at $10.98 (I) Footnote: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.
- Common Stock: 2000 shares at $10.8 (I) Footnote: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

Inside Trans: GYRE THERAPEUTICS, INC. (GYRE) by Ma Songjiang (President) on 2025-03-03
- Common Stock: 2000 shares at $11.23 (I) Footnote: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.
- Common Stock: 2000 shares at $10.86 (I) Footnote: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

Inside Trans: GYRE THERAPEUTICS, INC. (GYRE) by Ma Songjiang (President) on 2025-02-27
- Common Stock: 2000 shares at $11.33 (I) Footnote: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.
- Common Stock: 2000 shares at $11.41 (I) Footnote: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

Inside Trans: GYRE THERAPEUTICS, INC. (GYRE) by Ma Songjiang (President) on 2025-02-25
- Common Stock: 2000 shares at $11.37 (I) Footnote: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.
- Common Stock: 2000 shares at $11.63 (I) Footnote: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

Now we've reached the end of the analysis.
You are now allotted tokens to make a final analysis summary.
Please don't use tokens to explain why you didn't have enough information.
Save that for the survey that comes last.

Finish the summary with two scores: MARKET_SCORE[] and PRICE_TARGET[]

If you think there's a 90% likelihood of an upward moves, say: MARKET_SCORE[90]
If you think the high today will be 50% higher, add to the price. Eg., If the price is $5.00, add 50%: PRICE_TARGET[$7.50]
PRICE_TARGET is the highest it is expected to rise today, so it cannot be less than the current price.

After you have completed that, please provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-10 words headline for news story from first summary paragraph]

GYRE_OUT_23 [2025-03-19 14:45:09 -0400] 561 Bytes | 131 tokens | Cum: 5005 tkns (62.56% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings & insider data
-> X3 <- Broader sector & market news
-> X4 <- General market sentiment & AI confidence levels
-> X5 <- AI's past analysis on similar companies
-> X6 <- More financial metrics
-> X7 <- AI's past analysis on this exact company
-> X8 <- Something altogether different (explain...)

GYRE_IN_25 [2025-03-19 14:45:10 -0400] 126 Bytes | 29 tokens | Cum: 5044 tkns (63.05% of 8k)
==========================================================================

====================================
[2025-03-19 11:45:10] # Analysis Completed
Elapsed Time: 35.44 seconds